Industrials · Industrial - Machinery · Synthos Deep Dive · 2026-07-03
| Verdict | Watch — systematic Synthos tier |
| Price (2026-07-02) | $139.05 · market cap ~$77.9B |
| Synthos scores (0–10) | Downside Risk 5 · Growth Quality 6 · Exponential Potential 3 |
| Synthos fair value (base case) | ~$144 → +3.5% · full range $100 (bear) – $167 (bull) |
| Street consensus | $162 (high $185 / low $125; 21 Buy · 17 Hold · 3 Sell) — context, not our anchor |
| Valuation | 32× trailing GAAP EPS · 21× FY26E · 19× FY27E · 17× FY28E adj · EV/S 4.9× · EV/EBITDA 17.5× |
| Exponential Potential | 3/10 · Low — ~7% forward revenue CAGR, mid-single-digit organic, growth not accelerating; a mature late-cycle compounder |
| Technicals | Range-bound/laggard — $139, −14% off 52-wk high, straddling 50/200-DMA, RSI 45, +2.6% 12-mo (SPY +20.6%) |
| Conviction | Low — 0 expert voices in the KB; verdict rests on fundamentals + quant only |
| Position sizing | If owned: dividend-industrial sleeve, ~1–2%; not a high-conviction overweight |
| Next catalyst | 2026-08-05 Q3'26 earnings (guide adj EPS $1.65–1.70) |
| Single biggest risk | Cyclical demand + integration/leverage from the AspenTech buy-in — organic growth stalling at a full-ish multiple |
One-line thesis. Emerson has successfully re-shaped itself from a sprawling conglomerate into a focused, higher-margin industrial-automation pure-play (FY25 revenue $18.0B, adjusted segment EBITA margin ~28%, ~$2.7B FCF), and management is now pivoting to shareholder returns — but the stock trades at a fair-to-full ~21× forward, has lagged the market badly (+2.6% vs SPY +20.6% over 12 months), and offers mid-single-digit organic growth with no acceleration. Good company, unexciting entry: Watch.
Emerson makes the "nervous system" of heavy industry — the valves, sensors, gauges, and control software that run oil refineries, chemical plants, power stations, water utilities, and factories. When a plant needs to measure a flow, control a temperature, or automate a process safely, Emerson gear is often what's inside. It's a 130-year-old St. Louis company that recently sold off its messier businesses (like the Copeland climate/compressor unit) to become a cleaner, more profitable automation company.
Is the stock cheap or expensive? Fairly priced — neither a bargain nor a bubble. You're paying about 21 times next year's profit for a solid but slow-growing business. Our verdict is Watch: it's a good company, but the stock has gone almost nowhere for a year while the market climbed ~20%, and at today's price there isn't much of a discount to get excited about.
Here's what our three scores mean in everyday terms:
The one big worry: Emerson's customers are cyclical (oil, gas, chemicals, factories). If global industrial demand softens, or the recent AspenTech software buy-in doesn't deliver, growth could stall — and there's little margin of safety in the price to cushion that.
Solid = price · dashed = 50-day average · dotted = 200-day average · amber = 52-week high/low. Price above both averages is an uptrend.
The shaded band widens when the stock gets more volatile. Riding the upper edge = strong momentum (sometimes stretched); the lower edge = weak / potentially oversold.
Above 70 (red band) = overbought, below 30 (green band) = oversold. Currently 44.
Blue crossing above amber (bars flip green) = momentum turning up; below (bars red) = turning down. Bar height = the size of that gap.
Solid = EMR · dashed = S&P 500 · dotted = XLI (sector). A rising line means it is beating that benchmark — the sector line shows whether it is a leader or laggard within its own group.
Darker bars = actual results, brighter = analyst estimates. Taller bars to the right = expected growth.
Every claim reconciles to a real claim_id in the Synthos knowledge base — this is the evidence the verdict is built on, not vibes. Management (the company itself) is shown but half-weighted; one cautionary voice is included on purpose.
Emerson Electric (NYSE: EMR) is a global industrial-automation company headquartered in St. Louis, Missouri, founded in 1890. Over the past few years management has executed a deliberate portfolio transformation: it exited its climate-technologies business (Copeland), created a joint venture, and doubled down on process/discrete automation, culminating in the full buy-in of AspenTech (industrial software) completed in FY25. The result is a more focused, higher-margin, software-and-control-weighted franchise than the old Emerson conglomerate. Fiscal year ends September 30.
Revenue mix (FY2025, from filings):
End-markets are classic process and hybrid industries: oil & gas, refining, chemicals, power & renewables, life sciences, food & beverage, metals & mining, and water utilities — long-cycle, capital-intensive, and cyclical.
There is no expert coverage of EMR in the Synthos knowledge base. total_claims = 0; there are zero net-bullish or cautionary voices in the panel. Unlike our conviction-track names (where independent expert claims drive the call), this verdict is entirely fundamentals- and quant-driven — built from the FMP financials, analyst estimates, management's own SEC-filed guidance (§9, half-weighted), and Synthos's scoring framework.
Honesty is the product: we will not manufacture conviction where none exists. Readers should weight this note accordingly — it reflects the numbers and the quant model, not a distilled panel of investor voices. The Street's sell-side view (21 Buy / 17 Hold / 3 Sell, consensus "Buy," PT $162) is shown throughout as context, not as a Synthos conviction signal.
The one-glance judgment — three scores, 0–10, each anchored to real metrics (not probabilities we can't honestly calibrate):
| Score | 0–10 | The read |
|---|---|---|
| Downside Risk (lower = safer) | 5 · Moderate | Investment-grade (rating B, "Buy" letter) and a Dividend King, but net-debt/EBITDA ~2.4× (up sharply after the AspenTech buy-in), beta 1.25, cyclical end-markets, and a fair-to-full 21× forward leave limited margin of safety. |
| Growth Quality | 6 · Decent | ~7% forward revenue CAGR and ~14% adjusted-EPS CAGR (margin expansion + buyback), high returns on the automation core (ROCE ~12%, ROIC ~8% depressed by goodwill), sticky software mix — solid, not spectacular. |
| Exponential Potential | 3 · Low | Mature late-cycle industrial. Organic growth is mid-single-digit and not accelerating; a $78B cap in a slow TAM caps upside. This is a compounder, not an exponential. |
The three cases (our own scenario model — assumptions shown; each target is a ~12–18-month fair value). We deliberately do not attach probabilities: the base case is by definition the expected path, so a weighted blend would just restate it with false precision. Instead the cases bound the range, and the scores above summarize them.
| Case | Key assumptions | Fair value |
|---|---|---|
| Bull | Automation capex cycle re-accelerates; Software & Control compounds double-digit; AspenTech synergies land; margins push toward 30%. FY27E adj EPS beats to ~$7.60 (vs $7.21 cons); multiple re-rates to ~22×. | ~$167 (+20%) |
| Base (our anchor) | Guidance roughly holds — FY26 adj EPS ~$6.50, FY27E adj EPS $7.21; a steady ~7% top-line / low-double-digit EPS compounder earns a ~20× multiple. | ~$144 (+3.5%) |
| Bear | Industrial recession / oil & gas capex pullback; Middle East and China demand soften; buy-in leverage bites. FY27E adj EPS misses to ~$6.70; multiple de-rates to ~15×. | ~$100 (−28%) |
Synthos fair value = the base case, ~$144 (+3.5%), with the full $100–$167 span as the honest range. Our base sits below the Street's $162 consensus: we apply a more conservative ~20× forward multiple and take the cyclicality and 2.4× leverage more seriously than the sell side. The thin ~3.5% base-case upside is precisely why the verdict is Watch, not Buy — we'd want a pullback toward the low-$120s (nearer the 52-week low and a mid-teens multiple) to build a real margin of safety. This is a tracked call — the Forecaster Scorecard grades it once it matures.
Synthos separates compounders (durable high returns on capital) from exponentials (accelerating, multi-baggers-from-here). EMR is a quality compounder with essentially no exponential profile:
Exponential Potential: Low (3/10). Own EMR — if at all — for steady low-double-digit EPS compounding and a rising dividend, not for growth. A small, accelerating automation/software name would score far higher on this axis; EMR is the opposite end of the spectrum.
EMR is fairly-to-fully valued, not cheap and not expensive. On trailing GAAP it looks rich (32× EPS) but that's distorted by intangible amortization; the cleaner read is forward adjusted P/E: 21× FY26E → 19× FY27E → 17× FY28E → ~13× FY30E, alongside EV/EBITDA 17.5× and EV/S 4.9×. For a ~7%-revenue / low-double-digit-EPS grower with ~28% EBITDA margins, ~20× is a reasonable multiple — which is exactly the problem: at today's price you're paying full freight for a fair business, with a PEG (forward) near 3×.
Our base-case ~$144 applies ~20× to FY27E adjusted EPS of $7.21. The Street's $162 consensus (high $185, low $125) implies a richer ~22–23× on FY27 — we think that's optimistic for a cyclical at this point in the cycle, so we anchor below the sell side. The dividend yield (~1.6%, a Dividend King with 60+ consecutive years of increases) provides a modest floor. Bottom line: not a value entry. A pullback toward the low-$120s (near the 52-week low, ~15–16× forward) would offer the margin of safety that today's price does not.
Emerson's moat is real but not a fortress: (1) installed-base lock-in — process-control systems (DeltaV), measurement instruments, and valves are deeply embedded in customer plants with high switching costs and decades-long replacement cycles; (2) breadth + software — the AspenTech buy-in adds sticky industrial-software (asset optimization, simulation) that raises switching costs and margin; (3) safety/reliability reputation in mission-critical applications where downtime is enormously costly. Against that, end-markets are cyclical and capex-driven, and Emerson competes with large, capable peers across every product line.
Peer set (market cap): the closest automation comps aren't all in the FMP peer list, but from it: Parker-Hannifin $121B, Cummins $91B, Illinois Tool Works $78B, Johnson Controls $86B, Cintas $73B, Howmet $108B, Waste Management $93B, TransDigm $75B, Northrop Grumman $78B, UPS $83B. The truest automation rivals in the wider market are Honeywell, Siemens, ABB, Schneider Electric, and Rockwell Automation — a well-capitalized, sophisticated field. EMR's ~28% EBITDA margin and software mix are competitive strengths within it; it is neither the clear leader nor a laggard on quality.
- Net sales growth ~4.5% (Q3 ~5.5%); underlying/organic sales growth ~3% (Q3 ~5%).
- Adjusted EPS $6.45–$6.55 for the full year ($1.65–1.70 for Q3); GAAP EPS $4.79–4.89.
- Operating cash flow $4.0–4.1B; free cash flow $3.5–3.6B.
- Capital return: $2.2B planned ($1.0B buyback + $1.2B dividends).
- CEO Karsanbhai framed FY26 as "developing largely as expected with a strong second half, supported by orders momentum and a robust backlog," while flagging the Middle East conflict as a Q2 sales headwind. Treat as management's self-interested view; we half-weight it. This is a genuine, detailed earnings-release guide (not cover boilerplate), so it is summarized here as management's own words.
Thesis tripwires (what would change the call): two consecutive quarters of negative underlying order growth; a cut to the FY adjusted-EPS or FCF guide; net-debt/EBITDA rising rather than falling; or Software & Control decelerating to low single digits. Conversely, a pullback to the low-$120s with intact guidance would upgrade this from Watch toward Buy — Tactical.
Watch. Emerson is a genuinely improved company — a focused, high-margin (~28% EBITDA) automation franchise with a sticky installed base, a growing software mix, ~$2.7B (rising to ~$3.5B guided) free cash flow, and a Dividend-King payout. But at ~$139 it trades at a fair-to-full ~21× forward for mid-single-digit organic growth, our base-case fair value (~$144) sits only ~3.5% above spot and below the Street's $162, the balance sheet carries fresh ~2.4× leverage, and the stock has been a persistent market laggard. There is no expert conviction in the Synthos KB to lean on. The quality is real; the entry is not compelling.
claim_ids are cited because none exist. Fabricated conviction is structurally impossible (claim-ID reconciliation), and we state the absence of coverage plainly rather than inventing a panel.